On March 9, 2022 Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") reported that its wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of active ingredients (Press release, Sirona Biochem, MAR 9, 2022, View Source [SID1234609769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The project will be financed in partnership with the French government and will include the University of Rouen in Normandy, the Engineering school INSA of Rouen and the CNRS (The French National Centre for Scientific Research – among the world’s leading research institutions) to develop "flow chemistry", an advanced technology for multistep syntheses of compounds.

Flow chemistry allows for a continuous flow manufacturing of organic molecules rather than batch type manufacturing. The technology provides several advantages to the process development of Sirona’s compounds and actives by reducing the cost of production, preventing the formation of secondary products and improving the security of certain chemical reactions.

The French government will co-finance and hire a postdoctoral student full time on the project and will allow the free use of a facility at the university as well as access to the specialized equipment required to develop the process. The student will share time between TFChem’s laboratory in Val de Reuil and the Institute of Organic chemistry in Rouen (IRCOF). The contract will be for one year.